MedTrace Logo

Predicting Bleeding Risk on Anticoagulant Therapy for Venous Thromboembolism

NCT00788736 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2537

Last updated 2016-10-27

No results posted yet for this study

Summary

The main objective of the study is to develop or validate a clinical prediction rule for major bleeding in patients on oral anticoagulant therapy who have been safely anticoagulated without bleeding or venous thromboembolism (VTE) recurrence for at least 3 months since diagnosis and are being considered for long-term oral anticoagulant therapy.

Conditions

  • Venous Thromboembolism

Sponsors & Collaborators

  • Heart and Stroke Foundation of Ontario

    collaborator OTHER

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Ottawa Hospital Research Institute

    lead OTHER

Principal Investigators

  • Phil S Wells, MD, MSc · Ottawa Hospital Research Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2016-09-30
Completion
2016-10-31

Countries

  • United States
  • Canada
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00788736 on ClinicalTrials.gov